Cargando…
Pharmacogenetics and personalized treatment of type 2 diabetes
Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health and economic consequences. T2DM patients are often treated with more than one drug, including oral antidiabetic drugs (OAD) and drugs used to treat diabetic complications, such as dyslipidemia and hypertension. If genet...
Autores principales: | , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Croatian Society of Medical Biochemistry and Laboratory Medicine
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900064/ https://www.ncbi.nlm.nih.gov/pubmed/23894862 http://dx.doi.org/10.11613/BM.2013.020 |
_version_ | 1782300653405601792 |
---|---|
author | Semiz, Sabina Dujic, Tanja Causevic, Adlija |
author_facet | Semiz, Sabina Dujic, Tanja Causevic, Adlija |
author_sort | Semiz, Sabina |
collection | PubMed |
description | Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health and economic consequences. T2DM patients are often treated with more than one drug, including oral antidiabetic drugs (OAD) and drugs used to treat diabetic complications, such as dyslipidemia and hypertension. If genetic testing could be employed to predict treatment outcome, appropriate measures could be taken to treat T2DM more efficiently. Here we provide a review of pharmacogenetic studies focused on OAD and a role of common drug-metabolizing enzymes (DME) and drug-transporters (DT) variants in therapy outcomes. For example, genetic variations of several membrane transporters, including SLC22A1/2 and SLC47A1/2 genes, are implicated in the highly variable glycemic response to metformin, a first-line drug used to treat newly diagnosed T2DM. Furthermore, cytochrome P450 (CYP) enzymes are implicated in variation of sulphonylurea and meglitinide metabolism. Additional variants related to drug target and diabetes risk genes have been also linked to interindividual differences in the efficacy and toxicity of OAD. Thus, in addition to promoting safe and cost-effective individualized diabetes treatment, pharmacogenomics has a great potential to complement current efforts to optimize treatment of diabetes and lead towards its effective and personalized care. |
format | Online Article Text |
id | pubmed-3900064 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2013 |
publisher | Croatian Society of Medical Biochemistry and Laboratory Medicine |
record_format | MEDLINE/PubMed |
spelling | pubmed-39000642014-01-23 Pharmacogenetics and personalized treatment of type 2 diabetes Semiz, Sabina Dujic, Tanja Causevic, Adlija Biochem Med (Zagreb) Review Type 2 diabetes mellitus (T2DM) is a worldwide epidemic with considerable health and economic consequences. T2DM patients are often treated with more than one drug, including oral antidiabetic drugs (OAD) and drugs used to treat diabetic complications, such as dyslipidemia and hypertension. If genetic testing could be employed to predict treatment outcome, appropriate measures could be taken to treat T2DM more efficiently. Here we provide a review of pharmacogenetic studies focused on OAD and a role of common drug-metabolizing enzymes (DME) and drug-transporters (DT) variants in therapy outcomes. For example, genetic variations of several membrane transporters, including SLC22A1/2 and SLC47A1/2 genes, are implicated in the highly variable glycemic response to metformin, a first-line drug used to treat newly diagnosed T2DM. Furthermore, cytochrome P450 (CYP) enzymes are implicated in variation of sulphonylurea and meglitinide metabolism. Additional variants related to drug target and diabetes risk genes have been also linked to interindividual differences in the efficacy and toxicity of OAD. Thus, in addition to promoting safe and cost-effective individualized diabetes treatment, pharmacogenomics has a great potential to complement current efforts to optimize treatment of diabetes and lead towards its effective and personalized care. Croatian Society of Medical Biochemistry and Laboratory Medicine 2013-06-15 /pmc/articles/PMC3900064/ /pubmed/23894862 http://dx.doi.org/10.11613/BM.2013.020 Text en ©Copyright by Croatian Society of Medical Biochemistry and Laboratory Medicine This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/3.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Semiz, Sabina Dujic, Tanja Causevic, Adlija Pharmacogenetics and personalized treatment of type 2 diabetes |
title | Pharmacogenetics and personalized treatment of type 2 diabetes |
title_full | Pharmacogenetics and personalized treatment of type 2 diabetes |
title_fullStr | Pharmacogenetics and personalized treatment of type 2 diabetes |
title_full_unstemmed | Pharmacogenetics and personalized treatment of type 2 diabetes |
title_short | Pharmacogenetics and personalized treatment of type 2 diabetes |
title_sort | pharmacogenetics and personalized treatment of type 2 diabetes |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3900064/ https://www.ncbi.nlm.nih.gov/pubmed/23894862 http://dx.doi.org/10.11613/BM.2013.020 |
work_keys_str_mv | AT semizsabina pharmacogeneticsandpersonalizedtreatmentoftype2diabetes AT dujictanja pharmacogeneticsandpersonalizedtreatmentoftype2diabetes AT causevicadlija pharmacogeneticsandpersonalizedtreatmentoftype2diabetes |